Andrew C. Karlinski’s Bristol-Myers Squibb BMY Stock Holding History

Andrew C. Karlinski’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-42	Closed	-$3K	–	20
2022 Q3	$3K	Hold	42	–	–	﹤0.01%	200
2022 Q2	$3K	Buy	42 +1	+2%	+$76	﹤0.01%	232
2022 Q1	$3K	Sell	41 -7	-15%	-$470	0.01%	231
2021 Q4	$3K	Buy	+48	New	+$2.82K	0.01%	165

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Andrew C. Karlinski's BMY Position: Q4 2022 in Review

Andrew C. Karlinski sold out of Bristol-Myers Squibb (BMY) in Q4 2022, closing a stake of 42 shares — an estimated $3K sold.

Andrew C. Karlinski first reported a position in BMY in Q4 2021 and held it in 4 quarters. The position peaked at $3K in Q3 2022. 2,600 funds tracked by Wall St. Rank hold BMY as of Q4 2022.

Andrew C. Karlinski reported no remaining Bristol-Myers Squibb position as of Q4 2022 after selling out during the quarter.
Andrew C. Karlinski sold 42 Bristol-Myers Squibb shares in Q4 2022, an estimated $3K.
Andrew C. Karlinski first reported a position in Bristol-Myers Squibb in Q4 2021 and held it in 4 quarters.
Andrew C. Karlinski's Bristol-Myers Squibb position peaked at $3K in Q3 2022.
2,600 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2022.

Based on Andrew C. Karlinski's 13F filing for Q4 2022.